178k views
5 votes
Suppose you are CEO of a pharmaceutical company and there are early reports of potential bad reactions to one of your drugs. This information would be regarded as more relevant or reliable?

User Pernille
by
6.8k points

1 Answer

3 votes

Final answer:

In the context of a pharmaceutical company, early reports of bad reactions to a drug are both relevant and reliable. Relevance means the data is pertinent to the drug's safety and efficacy, while reliability refers to the consistency and trustworthiness of the data. The source's credibility and the data's consistency with known information are important in determining its reliability.

Step-by-step explanation:

Regarding the question of whether the information about potential bad reactions to a drug would be regarded as more relevant or reliable, it's important to understand the distinction between these two concepts. Relevance refers to how pertinent the information is to the issue at hand, which in this case is the safety and efficacy of a pharmaceutical drug. Reliability speaks to the trustworthiness and consistency of the data. In the scenario where you are the CEO of a pharmaceutical company facing early reports of bad reactions, both relevance and reliability are crucial.

Considering the scenario where studies are conducted to determine the effectiveness of a viral antibody drug, the collected data on the average length of time patients live once starting the treatment is certainly relevant as it directly impacts the company's understanding of the drug's efficacy. In assessing the quality of information, sources like the World Health Organization or peer-reviewed medical journals are generally seen as more reliable compared to online forums or non-expert opinions. Good quality data is critical when conducting statistical analyses and making informed decisions.

Furthermore, when monitoring a drug post-approval, pharmacovigilance systems are in place to ensure long-term safety and effectiveness. It is imperative to investigate and address any potential adverse reactions or errors to maintain the integrity of the pharmaceutical product and protect public health. Thus, any such early reports should be considered both relevant in terms of the potential impact on patient's health and reliable depending on the source and the data's consistency with previously known information.

User Nomiluks
by
7.3k points